Inventiva Announces A Late Breaker Abstract And Two Additional Abstracts On Its Lead Compound, Lanifibranor, At The AASLD The Liver Meeting 2023
Inventiva Announces A Late Breaker Abstract And Two Additional Abstracts On Its Lead Compound, Lanifibranor, At The AASLD The Liver Meeting 2023
Inventiva 在 2023 年 AASLD 肝脏会议上宣布了一份关于其主要化合物 Lanifibranor 的最新摘要和另外两份摘要
The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.
Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected for presentation. The two abstracts show:
the correlation between the increase of adiponectin under lanifibranor and the improvement of histological and serum markers of NASH severity both in terms of activity and fibrosis.
the improvement of liver histology and markers of cardiometabolic health in patients with NASH treated with lanifibranor, independent of PNPLA3 genotype.
由肯尼思·库西博士领导的评估T2D和MASLD患者的拉尼菲布兰诺的II期研究被选为晚期突破者。
评估拉尼菲布兰用于治疗NASH患者的NATIVE IIb期临床试验的另外两份科学摘要已被选出进行介绍。这两份摘要显示：
在活性和纤维化方面，lanifibranor下脂联素的增加与NASH严重程度的组织学和血清标志物的改善之间的相关性。
使用 lanifibranor 治疗 NASH 患者的肝脏组织学和心脏代谢健康标志物的改善，与 PNPLA3 基因型无关。
Daix (France), Long...
戴克斯...
登录免费看全文
登录/注册
资讯热榜
更新时间